Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motretinide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Motretinide is a synthetic retinoid and an aromatic retinoic acid derivative used as a topical agent for the treatment of mild to moderate acne. It exhibits antikeratonizing activity, helping to normalize follicular keratinization and reduce microcomedone formation in acne-prone skin. The drug acts by modulating nuclear receptors involved in skin cell differentiation, similar to other retinoids. Motretinide was initially developed by F. Hoffmann-La Roche Ltd., with first approval in Switzerland in 1981 for the indication of acne vulgaris[2][3][4][5].
- Brand names
- TasmadermAcretinTretam
- Other names
- MotretinidMotretinida
02
Targets
RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on motretinide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motretinide.